Boudou-Rouquette P - Search Results

1

SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.

Velut Y, Decroix E, Blons H, Alifano M, Leroy K, Petitprez F, Boni A, Garinet S, Biton J, Cremer I, Wislez M, Boudou-Rouquette P, Arrondeau J, Goldwasser F, Fournel L, Damotte D, Mansuet-Lupo A. Velut Y, et al. Lung Cancer. 2022 Jul;169:13-21. doi: 10.1016/j.lungcan.2022.05.001. Epub 2022 May 5. Lung Cancer. 2022. PMID: 35597058

2

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.

Mir O, Alexandre J, Coriat R, Ropert S, Boudou-Rouquette P, Bui T, Chapron J, Durand JP, Dusser D, Goldwasser F. Mir O, et al. Invest New Drugs. 2012 Aug;30(4):1756-60. doi: 10.1007/s10637-011-9690-9. Epub 2011 May 26. Invest New Drugs. 2012. PMID: 21614447

3

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.

Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F. Arrondeau J, et al. Invest New Drugs. 2012 Oct;30(5):2046-9. doi: 10.1007/s10637-011-9764-8. Epub 2011 Oct 29. Invest New Drugs. 2012. PMID: 22038662

4

Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications.

Mir O, Coriat R, Boudou-Rouquette P, Durand JP, Goldwasser F. Mir O, et al. Ann Oncol. 2012 Jan;23(1):280-281. doi: 10.1093/annonc/mdr525. Epub 2011 Nov 4. Ann Oncol. 2012. PMID: 22056851 Free article. No abstract available.

5

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, Coriat R, Goldwasser F. Tlemsani C, et al. Target Oncol. 2011 Dec;6(4):253-8. doi: 10.1007/s11523-011-0201-x. Epub 2011 Nov 17. Target Oncol. 2011. PMID: 22090260 Review.

6

Objective response to sorafenib in advanced clear-cell sarcoma.

Mir O, Boudou-Rouquette P, Larousserie F, Babinet A, Dumaine V, Anract P, Goldwasser F. Mir O, et al. Ann Oncol. 2012 Mar;23(3):807-809. doi: 10.1093/annonc/mds005. Epub 2012 Jan 24. Ann Oncol. 2012. PMID: 22274882 Free article. No abstract available.

7

Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.

Mir O, Boudou-Rouquette P, Larousserie F, Blanchet B, Babinet A, Anract P, Goldwasser F. Mir O, et al. Anticancer Drugs. 2012 Aug;23(7):745-8. doi: 10.1097/CAD.0b013e3283514b8c. Anticancer Drugs. 2012. PMID: 22331039

8

Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.

Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F. Mir O, et al. Lung Cancer. 2012 Jul;77(1):104-9. doi: 10.1016/j.lungcan.2012.01.014. Epub 2012 Feb 24. Lung Cancer. 2012. PMID: 22364783

9

Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.

Mir O, Coriat R, Boudou-Rouquette P, Ropert S, Durand JP, Cessot A, Mallet V, Sogni P, Chaussade S, Pol S, Goldwasser F. Mir O, et al. Med Oncol. 2012 Dec;29(4):2793-9. doi: 10.1007/s12032-012-0208-x. Epub 2012 Mar 17. Med Oncol. 2012. PMID: 22427209

10

Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study.

Mir O, Durand JP, Boudou-Rouquette P, Giroux J, Coriat R, Cessot A, Ropert S, Goldwasser F, Gaillard R. Mir O, et al. Support Care Cancer. 2012 Sep;20(9):2235-9. doi: 10.1007/s00520-012-1503-y. Epub 2012 May 30. Support Care Cancer. 2012. PMID: 22644261

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters